Publisher Correction: Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19

Affiliations

• ¹ Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, USA. kchew@mednet.ucla.edu.
• ² Harvard T.H. Chan School of Public Health, Boston, MA, USA.
• ³ Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA, USA.
• ⁴ Department of Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
• ⁵ Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
• ⁶ Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
• ⁷ Department of Medicine, University of Washington, Seattle, WA, USA.
• ⁸ National Institutes of Health, Bethesda, MD, USA.
• ⁹ Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
• ¹⁰ Ohio State University Wexner Medical Center, Columbus, OH, USA.
• ¹¹ Eli Lilly and Company, San Diego, CA, USA.
• ¹² UNMC Center for Drug Discovery, University of Nebraska Medical Center, Omaha, NE, USA.
• ¹³ Clinical Pharmacology & Pharmacometrics, Jounce Therapeutics, Cambridge, MA, USA.
• ¹⁴ Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, USA.
• ¹⁵ Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, USA.
• ¹⁶ Department of Medicine, University of California, San Diego, La Jolla, CA, USA.